Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLA-A2+ type 1 diabetic patients
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
Hypoglycemia (Low Blood Sugar) Both berberine and GLP-1 agonists are effective at lowering blood sugar
Your cost depends on your treatment plan, set at your free consultation
For these women, the waiting period before starting GLP-1 treatment can feel especially frustrating
L-carnitine, the main ingredient of the product, is a compound naturally produced by the human body and consisting partly of amino acids
